{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.8","upperLimit":"23.8","value":"20.1"},{"groupId":"OG001","lowerLimit":"19.4","upperLimit":"49.8","value":"28.0"},{"groupId":"OG002","lowerLimit":"9.2","upperLimit":"19.4","value":"13.1"},{"groupId":"OG003","lowerLimit":"11.1","upperLimit":"17.0","value":"14.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"23"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"The efficacy and safety of LDE225 200mg laBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG000","title":"LDE225 200mg laBCC"},{"description":"The efficacy and safety of LDE225 800mg laBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG001","title":"LDE225 800mg laBCC"},{"description":"The efficacy and safety of LDE225 200mg mBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG002","title":"LDE225 200mg mBCC"},{"description":"The efficacy and safety of LDE225 800mg mBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG003","title":"LDE225 800mg mBCC"}],"paramType":"MEDIAN","populationDescription":"The primary efficacy analysis set (pEAS) was a subset of the full analysis set (FAS) including patients with laBCC with tumors that were adequately assessed by MRI or photography or both, \\& including all patients with mBCC included in the FAS which comprised all patients who were assigned study treatment irrespective of receiving it.","reportingStatus":"POSTED","timeFrame":"42 months","title":"Progression-free Survival (PFS) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)","type":"SECONDARY","unitOfMeasure":"Months"}